Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma MEDSTAT_JS MEDSTAT_CSS

Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma

CD30- and PD-1-targeted therapies are showing great promise in improving outcomes for patients with classical Hodgkin lymphoma. In this virtual roundtable, Dr. Sharon Castellino leads a discussion with Dr. Alex Herrera and Dr. Kara Kelly about the biological significance and latest clinical trial data for these therapies. The panel also addresses the gap in treatment between adult and adolescent and young adult (AYA) populations.

Video 1: Impact of CD30 and PD-L1 therapies

The roundtable begins with a review of how CD30- and PD-1-targeted therapies are challenging the treatment paradigm. The panel also discusses balancing the benefits of therapy and potential toxicities such as peripheral neuropathy.

Up Next

Video 1: Impact of CD30 and PD-L1 therapies
Video 2: Closing the gap between children and adult populations
Video 3: Recent clinical trial data and the future of combination therapy

MEDSTAT_LATEST_NEWS_WIDGET

About the Panel

Dr. Stock Photo

Sharon M. Castellino, MD, MSc

  • Director,
  • Children's Healthcare of Atlanta,
  • Atlanta, Georgia
Dr. Oh Photo

Alex F. Herrera, MD

  • Assistant Professor,
  • City of Hope Medical Center,
  • Duarte, California
Dr. Kelly Photo

Kara M. Kelly, MD

  • Professor,
  • Roswell Park Comprehensive Cancer Center,
  • Buffalo, NY
Disclosures

Sharon M. Castellino, MD, MSc, has disclosed the following relevant financial relationships:
Received research grant from: National Cancer Institute

Alex F. Herrera, MD, has disclosed the following relevant financial relationships:
Received research grant from: Bristol-Myers Squibb; Merck; Genentech; Seattle Genetics
Received income in an amount equal to or greater than $250 from: Bristol-Myers Squibb; Genentech; Seattle Genetics; Karyopharm

Kara M. Kelly, MD, has nothing to disclose.